Chemomab Therapeutics (CMMB)
(Delayed Data from NSDQ)
$1.40 USD
+0.18 (14.75%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $1.47 +0.07 (5.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Chemomab Therapeutics Ltd. Sponsored ADR [CMMB]
Reports for Purchase
Showing records 1 - 11 ( 11 total )
Company: Chemomab Therapeutics Ltd. Sponsored ADR
Industry: Medical - Biomedical and Genetics
SPRING Trial Delivers, Raising PT to $9 from $7
Provider: Roth Capital Partners, Inc.
Analyst: WITTES J
Company: Chemomab Therapeutics Ltd. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Chemomab Therapeutics Ltd. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Chemomab Therapeutics Ltd. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Chemomab Therapeutics Ltd. Sponsored ADR
Industry: Medical - Biomedical and Genetics
PSC Ph 2 Enrollment Completes Early Accelerating Top-line Results to Mid-Year
Provider: Roth Capital Partners, Inc.
Analyst: WHITE J
Company: Chemomab Therapeutics Ltd. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Chemomab Therapeutics Ltd. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Resuming Coverage with a Buy and $7 PT
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Chemomab Therapeutics Ltd. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Biotechnology -Healthcare Coverage Update
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Chemomab Therapeutics Ltd. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Chemomab Therapeutics Ltd. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Chemomab Therapeutics Ltd. Sponsored ADR
Industry: Medical - Biomedical and Genetics
|